TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03424239
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5mg zoledronic acid
Study: NCT00903201
Drug: SB656933
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg
Study: NCT00903201
Drug: SB656933
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg
Study: NCT00903201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03082885
Drug: Thymosin-α1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.
Study: NCT01870609
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic defactinib tablet
Study: NCT01477567
Drug: LY3009385
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01477567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03042546
Drug: Calcium Sulfate
Normalized name: Calcium Sulfate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Sulfate with abx will be used in the defect
Study: NCT00185159
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: NCT03681197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
Study: NCT01155375
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator: Oral iron
Study: NCT00357942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthwash
Study: NCT00357942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for injection every 3 hour for 24 hours
Study: NCT03425838
Drug: CDK 4/6 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
Study: NCT03425838
Drug: Non-Steroidal Aromatase Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
Study: NCT00887250
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Losartan
Study: NCT01536353
Drug: AGSAV301
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, q.d.
Study: NCT01536353
Drug: Exforge 10/160
Normalized name: Exforge 10/160 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, q.d.
Study: NCT01737268
Drug: FK949E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT03376945
Drug: control cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
Study: NCT01306097
Drug: Zinc Supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg daily for under 1 years old children and 20mg daily for above 1 years old children
Study: NCT00160862
Drug: SLV317
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02941185
Drug: Devit-3 Oral Drop
Normalized name: DEVILS CLAW
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00093808
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05547659
Drug: Acetaminophen 1 G Oral Tablet
Normalized name: Acetaminophen 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1 G Oral Tablet preoperative in multi-modal group
Study: NCT00427336
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 by vein daily over 2 hours
Study: NCT05547659
Drug: Celecoxib 400Mg Oral Capsule
Normalized name: Celecoxib 400mg Oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
Study: NCT01190670
Drug: ASP015K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04364516
Drug: Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)
Study: NCT00176735
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00336544
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
Study: NCT04553419
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellulose capsules or suspension
Study: NCT00843349
Drug: LC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Lanthanum Carbonate
Study: NCT01570764
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
Study: NCT01570764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
Study: NCT01922999
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive placebo, 1mg melatonin or 3mg melatonin
Study: NCT00544219
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 i.v. per cycle
Study: NCT00544219
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 i.v. per cycle
Study: NCT01719133
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline solution
Study: NCT02926937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet;~Route of administration: oral
Study: NCT02215538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication appears identical to the active medication OROS methylphenidate
Study: NCT02425709
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive oral diclofenac 50 mg 1 hour before the procedure
Study: NCT02425709
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive an oral placebo 1 hour before the procedure
Study: NCT01719133
Drug: AllerT1
Approvals — FDA: no, EMA: no, PMDA: no
Description: synthetic peptide T1
Study: NCT01719133
Drug: AllerT2
Approvals — FDA: no, EMA: no, PMDA: no
Description: synthetic peptide T2
Study: NCT01719133
Drug: AllerT3
Approvals — FDA: no, EMA: no, PMDA: no
Description: synthetic peptide T3
Study: NCT01719133
Drug: AllerT4
Approvals — FDA: no, EMA: no, PMDA: no
Description: synthetic peptide T4
Study: NCT01559090
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
Study: NCT01559090
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
Study: NCT01559090
Drug: MEDI-546
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
Study: NCT01719133
Drug: AllerT5
Approvals — FDA: no, EMA: no, PMDA: no
Description: synthetic peptide T5
Study: NCT01719133
Drug: mix of AllerT1-T2-T3
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: mix of peptides T1, T2 and T3
Study: NCT01719133
Drug: mix of AllerT4-T5
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: mix T4-T5
Study: NCT04370977
Drug: Coartem™ (Artemether-lumefantrine combination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.
Study: NCT02723877
Drug: PQR309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
Study: NCT00655863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
Study: NCT00300196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mL/kg/hr
Study: NCT02014272
Drug: reference drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
Study: NCT04141163
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapeutic effect
Study: NCT01060462
Drug: Pts. w/ neutropenic fever associated w/ hematologic malignancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
Study: NCT04400318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection subcutaneous
Study: NCT00616161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03636256
Drug: NanoDoce (direct injection)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive NanoDoce injected into the index tumor resection site on the bladder wall, immediately following transurethral resection of the bladder tumor (TURBT)
Study: NCT00445692
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given Orally (PO)
Study: NCT03636256
Drug: NanoDoce (intravesical instillation) - Visit 2 Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive an initial intravesical instillation within 2 hours of direct injection.
Study: NCT03636256
Drug: NanoDoce (intravesical instillation) - Induction and Maintenance Instillations
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (NMIBC) will receive intravesical instillations in an Induction Period and a Maintenance Period.
Study: NCT00171275
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03766594
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid(R) 0.5mg tablets once daily for 3 months preconceptionally
Study: NCT03766594
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet apparently identical to Respatio(R) 25mg tablets, taken four times daily for 24 days preconceptionally starting first day of previous period
Study: NCT04688021
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 g/m2/day administered IV day -5 through -4.
Study: NCT03173339
Drug: High remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
Study: NCT03173339
Drug: Low remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil was administered as 0.1 mcg/kg/min.
Study: NCT00599001
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02517619
Drug: Prednisolone Acetate Ophthalmic (1%)
Normalized name: prednisolone acetate Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone Acetate (1%)
Study: NCT01655875
Drug: AMD3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
Study: NCT00885651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02348333
Drug: FYU-981, (Oral daily dosing for 7 days)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
Study: NCT02348333
Drug: Placebo, (Oral daily dosing for 7 days)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the placebo arm receive placebo.
Study: NCT00759291
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
Study: NCT06064448
Drug: Ningmitai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects took Ningmitai capsule, 0.38 g/capsule, 3 times a day, 4 capsules each time, after meals, and continued to treat for 4 weeks.
Study: NCT00607035
Drug: Olmesartan medoxomil + Hydrochlorothiazide
Normalized name: hydrochlorothiazide / olmesartan medoxomil Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
Study: NCT00482833
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
Study: NCT00482833
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
Study: NCT00879216
Drug: VA106483
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
Study: NCT00879216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
Study: NCT01958970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once weekly by IV infusion.~Cohort dose schedules:~* 3mg/kg weekly for 12 weeks~* 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks~* 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks
Study: NCT02469857
Drug: AB103 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01614743
Drug: Bacteriostatic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at baseline, incobotulinumtoxinA at 16 weeks
Study: NCT01144832
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: one capsule once daily
Study: NCT03601533
Drug: Phenol
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1,5 mL of 7% phenol will be injected in each of genicular nerves (superior, medial and lateral).
Study: NCT00378521
Drug: MQX-503
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04217590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
Study: NCT02251288
Drug: MF59 adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
Study: NCT03243760
Drug: CCI15106 7.5 mg capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
Study: NCT03243760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
Study: NCT03243760
Drug: Placebo-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
Study: NCT01419847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03185429
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2 by vein before the first cell infusion.
Study: NCT02190838
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: per os 3 mg daily
Study: NCT00406809
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution~Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.~Oral solution and tablets~Phase 2a dosing under 21 day continuous dosing.~- 150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.
Study: NCT00952198
Drug: ARRY-403, glucokinase activator; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose, escalating
Study: NCT00952198
Drug: Placebo; oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT03597308
Drug: 600mg of Ibuprofen every 6 hours as needed for pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg of Ibuprofen every 6 hours as needed for pain
Study: NCT03597308
Drug: 500mg of Acetaminophen every 6 hours as needed for pain
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg of Acetaminophen every 6 hours as needed for pain
Study: NCT00701077
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02821312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.~Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010.
Study: NCT02091063
Drug: ACY-1215
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
Study: NCT02373813
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During the open-label run-in period, methotrexate will be provided as 2.5 mg tablets.~During the double-blind treatment period, methotrexate will be provided as 2.5 mg capsules.
Study: NCT02373813
Drug: Placebo for methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate placebo capsules
Study: NCT01387256
Drug: medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: pregnancy termination with drugs
Study: NCT01074619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
Study: NCT00002566
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03443804
Drug: Test(DW1401)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: DW1401+Placebo of Stillen tab.
Study: NCT02963181
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.~Identify the mechanistic pathway of melatonin in blood pressure regulation
Study: NCT00405769
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 caps bid
Study: NCT01450098
Drug: LY2484595 Reference Formulation (RF)
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00561951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corresponding placebo tablets OD for 12 weeks